Genomma Lab Internacional, S.A.B. de C.V. GNMLF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.60% | 67.31% | -4.04% | -9.24% | -5.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.60% | 67.31% | -4.04% | -9.24% | -5.05% |
| Cost of Revenue | 5.56% | 67.83% | -2.45% | -5.86% | -4.42% |
| Gross Profit | 2.46% | 67.02% | -4.96% | -11.13% | -5.42% |
| SG&A Expenses | 3.51% | 68.58% | -5.13% | -12.91% | -5.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 142.03% | -31.64% | 6.02% | 9.60% | -273.48% |
| Total Operating Expenses | 5.54% | 68.33% | -3.89% | -9.72% | -6.02% |
| Operating Income | -3.52% | 63.59% | -4.63% | -7.44% | -1.36% |
| Income Before Tax | 12.34% | 45.69% | -18.31% | -19.59% | -10.52% |
| Income Tax Expenses | 7.76% | 55.45% | -7.18% | -1.04% | -13.63% |
| Earnings from Continuing Operations | 14.42% | 41.55% | -22.70% | -26.63% | -9.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -658.30% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.02% | 116.18% | 0.97% | -0.44% | -35.24% |
| EBIT | -3.52% | 63.59% | -4.63% | -7.44% | -1.36% |
| EBITDA | -3.14% | 56.48% | -3.71% | -6.70% | 1.03% |
| EPS Basic | -15.02% | 96.35% | 47.35% | 45.21% | 9.81% |
| Normalized Basic EPS | -22.79% | 80.22% | 5.11% | 2.58% | 12.80% |
| EPS Diluted | -15.02% | 96.35% | 47.35% | 45.21% | 9.81% |
| Normalized Diluted EPS | -22.79% | 80.22% | 5.11% | 2.58% | 12.80% |
| Average Basic Shares Outstanding | 23.17% | -9.95% | -7.53% | -6.17% | -4.79% |
| Average Diluted Shares Outstanding | 23.17% | -9.95% | -7.53% | -6.17% | -4.79% |
| Dividend Per Share | -52.19% | -25.83% | -12.88% | -19.34% | 207.39% |
| Payout Ratio | -0.33% | -0.14% | 0.03% | -0.03% | 0.37% |